Security key
17322U207
- Security type / class
- Equity / COM
- Total 13F shares
- 1
- Total 13F value
- $1
- Share change
- +1
- SEC-reported price per share
- $1.00
- Number of holders
- 1
- Value change
- +$1
- Number of buys
- 1
Report period
Q3 2025
Institutions
1
Top holders
0
CTXR full security history
Ownership snapshot
Newer quarter: Q4 2025
Citius Pharmaceuticals, Inc. SEC filings
Citius Pharmaceuticals, Inc. company facts
Citius Pharmaceuticals, Inc. 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 17322U207
Recent filing periods:
Ownership snapshot
Top reported holders of CTXR - CITIUS PHARMACEUTICALS INC - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Leonard L. Mazur
Disclosed value leader
Leonard L. Mazur
Comparable rows
0/15
Latest evidence
08 Aug 2025
3/4/5
13F
Highest disclosed value: $574,299
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Leonard L. Mazur has the largest disclosed position value at $574.3K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Leonard L. Mazur's linked filing trail.
Disclosed position value
Top 5
Leonard L. Mazur
$574.3K
UBS Group AG
$306.8K
Cambridge Investment Research Adv...
$292K
HEIGHTS CAPITAL MANAGEMENT, INC
$254.2K
VANGUARD GROUP INC
$127.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Leonard L. Mazur |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$574,299
501,202 shares
mixed-class rows
|
— | 08 Aug 2025 |
| UBS Group AG |
13F
Company
|
—
denominator unverified
|
$306,755
192,927 shares
|
— | 30 Jun 2025 |
| Cambridge Investment Research Advisors, Inc. |
13F
Company
|
—
denominator unverified
|
$292,000
183,534 shares
|
— | 30 Jun 2025 |
| HEIGHTS CAPITAL MANAGEMENT, INC |
13F
Company
|
—
denominator unverified
|
$254,238
159,898 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$127,364
80,103 shares
|
— | 30 Jun 2025 |
| Myron Z. Holubiak |
3/4/5
Vice Chairman, Director
|
—
mixed-class rows
|
$124,316
106,501 shares
mixed-class rows
|
— | 08 Aug 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Archived quarter
Historical 13F summary for Q3 2025
This older quarter remains available as an indexed ownership summary. Detailed holder rows are no longer kept in the hot table for this period.